Current Edition


Immatics Enters into a Strategic Partnership with Genmab to Develop Next Generation Bispecific Cancer Immunotherapies

Immatics and Genmab to Combine Proprietary Technologies to Create Transformative Bispecific Therapies against Novel, Proprietary Tumor Targets Immatics to Receive $54 Million Upfront, Milestone Payments …

Continue Reading →

Nuance enters $58 M deal for non-opioid pain treatment in China

EXPAREL is a non-opioid option for achieving long-lasting pain control after surgery via infiltration into the surgical site or administration as an interscalene brachial plexus …

Continue Reading →